Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cassava Sciences (SAVA)
NASDAQ:SAVA
Holding SAVA?
Track your performance easily
SAVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.65 - $42.20
Previous Close$3.84
Volume15.86M
Average Volume (3M)4.32M
Market Cap
$184.74M
Enterprise Value$35.77M
Total Cash (Recent Filing)$148.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Mar 04, 2025EPS Estimate
-$0.58Last Dividend Ex-Date
Dec 13, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding48,110,475
10 Day Avg. Volume1,615,254
30 Day Avg. Volume4,318,830
Standard Deviation0.62
R-Squared0.00238
Alpha0.17
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)7.53
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda2.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
Cassava Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAnalyst maintains a bullish view on prospects for the Phase 3 studies to be positive as previous Phase 2 studies showed simufilam was safe, well-tolerated, and has potential to modify progression of cognitive degeneration in Alzheimer's patients.
Financial PerformanceCassava Sciences has sufficient cash reserves operationally through 2026 despite the trial setbacks.
Regulatory AdvancementIf positive primary outcomes are observed in mild Alzheimer's patients, Cassava Sciences has a strong scientific rationale to further engage with the FDA, potentially benefiting simufilam's regulatory advancement.
Bears Say
Clinical Trial ResultsThe ReThink-ALZ Phase 3 trial with simufilam did not meet its primary and secondary endpoints in Alzheimer’s patients.
Investment RisksInvestment thesis risks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential need to raise additional funds under poor market conditions.
Stock RatingAnalyst downgrades the stock rating to Neutral from Buy, removing forecasts for simufilam approval and related revenues.
---
Ownership Overview
7.63% Insiders
7.81% Mutual Funds
8.84% Other Institutional Investors
67.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAVA FAQ
What was Cassava Sciences’s price range in the past 12 months?
Cassava Sciences lowest stock price was $3.65 and its highest was $42.20 in the past 12 months.
What is Cassava Sciences’s market cap?
Currently, no data Available
When is Cassava Sciences’s upcoming earnings report date?
Cassava Sciences’s upcoming earnings report date is Mar 04, 2025 which is in 72 days.
How were Cassava Sciences’s earnings last quarter?
Cassava Sciences released its earnings results on Nov 07, 2024. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.73 by $0.15.
Is Cassava Sciences overvalued?
According to Wall Street analysts Cassava Sciences’s price is currently Overvalued.
Does Cassava Sciences pay dividends?
Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here
What is Cassava Sciences’s EPS estimate?
Cassava Sciences’s EPS estimate is -$0.58.
How many shares outstanding does Cassava Sciences have?
Cassava Sciences has 48,110,474 shares outstanding.
What happened to Cassava Sciences’s price movement after its last earnings report?
Cassava Sciences reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.73. Following the earnings report the stock price went down -4.629%.
Which hedge fund is a major shareholder of Cassava Sciences?
Among the largest hedge funds holding Cassava Sciences’s share is Gallacher Capital Management LLC. It holds Cassava Sciences’s shares valued at 17M.
---
Cassava Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
SAVA Sentiment 79%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.30%
12-Months-Change
Fundamentals
Return on Equity
-10.98%
Trailing 12-Months
Asset Growth
29.69%
Trailing 12-Months
Company Description
Cassava Sciences
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
---
SAVA Earnings Call
Q3 2024
0:00 / 0:00
---
SAVA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering SAVA
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-82.70%
reiterated a buy rating 6 months ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -82.70% per trade.
---